ClinicalTrials.gg
CompletedNCT01398098Updated Nov 29, 2012

Measurement of Gastric Emptying During and After COLOKIT® Intake

A Phase 2 interventional study of Sodium phosphate in Colonoscopy, sponsored by Laboratoires Mayoly Spindler. Completed at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-11-29.

Sponsored by Laboratoires Mayoly Spindler · Phase 2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Ultra-sound study to assess changes in intragastric volume after bowel preparation.

02

Conditions studied

  • Colonoscopy
03

In context

Lead sponsor

Laboratoires Mayoly Spindler is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject who signed an to participate in the trial.
  • Subject affiliated with Social Security
  • Men and women aged 18 to 75 years.
  • Subject with an indication of scheduled outpatient colonoscopy.
  • colonoscopy performed within six hours after the second sequence COLOKIT®.
  • Subject able to swallow tablets.

Exclusion criteria

Exclusion Criteria:

  1. Women pregnant or likely to be (without ) or nursing.
  2. Subject having any of the following diseases or conditions:

    • allergy or to the product tested or any of its ,
    • nausea, vomiting or abdominal pain,
    • renal failure,
    • primary hyperparathyroidism associated with hypercalcemia,
    • congestive heart failure,
    • ascites,
    • a known or suspected bowel obstruction,
    • megacolon (congenital or acquired)
    • intestinal perforation,
    • ileus,
    • an inflammatory disease or suspected inflammatory bowel disease,
    • swallowing disorders,
    • known digestive motor disorders (gastroparesis, scleroderma, mega-esophagus),
    • diabetes mellitus (insulin or non insulin-dependent)
    • a history of gastric surgery (partial or total)
    • a to the anesthesia required for the completion of the colonoscopy,
    • Any clinical condition which, in the opinion of the investigator, would not allow the subject to perform the test in good conditions.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    COLOKIT®

    Drug: Sodium phosphate

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of patients with a residual antral volume lower than 20 mL

    Time frame: after 2nd treatment regimen intake

Secondary outcomes

  1. Adverse events

    Time frame: After drug intake

  2. Acceptability of COLOKIT®.

    Time frame: After drug intake

  3. Colonoscopy results

    Time frame: After colonoscopy.

07

Study locations

1 site
  • Cochin Hospital
    Paris, 75014, France
08

References and documents

Publications

  • Coriat R, Polin V, Oudjit A, Henri F, Dhooge M, Leblanc S, Delchambre C, Esch A, Tabouret T, Barret M, Prat F, Chaussade S. Gastric emptying evaluation by ultrasound prior colonoscopy: an easy tool following bowel preparation. World J Gastroenterol. 2014 Oct 7;20(37):13591-8. doi: 10.3748/wjg.v20.i37.13591. PubMed 25309090 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of May 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2011
First posted
Jul 20, 2011
Start
Oct 2011
Primary completionActual
May 2012
CompletionActual
Sep 2012
Last update
Nov 29, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01398098
Lead sponsor
Laboratoires Mayoly Spindler
Responsible party
Sponsor
First posted
Jul 20, 2011
Start date
Oct 2011
Primary completion
May 2012
Completion
Sep 2012
Last update
Nov 29, 2012

Study contacts

Stanislas CHAUSSADE, Professor
principal investigator · Cochin Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium phosphate

Start the discussion